{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:10:44Z","timestamp":1780913444641,"version":"3.54.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/mph.0000000000000474","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T12:12:02Z","timestamp":1447935122000},"page":"187-190","source":"Crossref","is-referenced-by-count":15,"title":["Outcomes of Patients With Relapsed Hepatoblastoma Enrolled on Children\u2019s Oncology Group (COG) Phase I and II Studies"],"prefix":"10.1097","volume":"38","author":[{"given":"Angela D.","family":"Trobaugh-Lotrario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka L.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Feusner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210209","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/pbc.24218","article-title":"Relapsed hepatoblastoma.","volume":"59","author":"Trobaugh-Lotrario","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R2-5-20210209","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1200\/JCO.2006.09.7204","article-title":". Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.","volume":"26","author":"Malogolowkin","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-5-20210209","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ejca.2012.10.003","article-title":". Relapses in hepatoblastoma patients: clinical characteristics and outcomeexperience of the international childhood liver tumour strategy group (siopel).","volume":"49","author":"Semeraro","year":"2013","journal-title":"Eur J Cancer"},{"key":"R4-5-20210209","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.ejca.2004.01.042","article-title":". Phase ii study of high-dose cyclophosphamide in relapsing andor resistant hepatoblastoma in children: a study from the siopel group.","volume":"40","author":"Cacciavillano","year":"2004","journal-title":"Eur J Cancer"},{"key":"R5-5-20210209","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","article-title":". Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastomaa phase II trial of the childhood liver tumour strategy group (siopel).","volume":"48","author":"Zsiros","year":"2012","journal-title":"Eur J Cancer"},{"key":"R6-5-20210209","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2002.20.1.88","article-title":". Phase i study of combination topotecan and carboplatin in pediatric solid tumors.","volume":"20","author":"Athale","year":"2002","journal-title":"J Clin Oncol"},{"key":"R7-5-20210209","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2004.07.110","article-title":". Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.","volume":"22","author":"Daw","year":"2004","journal-title":"J Clin Oncol"},{"key":"R8-5-20210209","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.mph.0000243657.64056.c3","article-title":". A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.","volume":"28","author":"Stempak","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"R9-5-20210209","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/pbc.23069","article-title":". Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma.","volume":"57","author":"Koh","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R10-5-20210209","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.1997.15.3.1190","article-title":". Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: A report from the childrens cancer group.","volume":"15","author":"Van Tornout","year":"1997","journal-title":"J Clin Oncol"},{"key":"R11-5-20210209","first-page":"887","article-title":"Fukumoto K, et al..","volume":"28","author":"Fukuzawa","year":"2012","journal-title":"Can we predict the prognosis of resectable hepatoblastoma from serum alpha-fetoprotein response during preoperative chemotherapy Pediatr Surg Int"},{"key":"R12-5-20210209","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1200\/JCO.2004.12.185","article-title":". Phase i study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Childrens Oncology Group study (advl0015).","volume":"22","author":"Blaney","year":"2004","journal-title":"J Clin Oncol"},{"key":"R13-5-20210209","doi-asserted-by":"crossref","first-page":"9179","DOI":"10.1200\/JCO.2004.01.0660","article-title":". Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a childrens oncology group study.","volume":"23","author":"Whitlock","year":"2005","journal-title":"J Clin Oncol"},{"key":"R14-5-20210209","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/1078-0432.672.11.2","article-title":". A phase i and pharmacokinetic study of ecteinascidin-743 (yondelis) in children with refractory solid tumors. A Childrens Oncology Group study.","volume":"11","author":"Lau","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R15-5-20210209","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1200\/JCO.2005.11.429","article-title":". Phase i and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Childrens Oncology Group study.","volume":"23","author":"Daw","year":"2005","journal-title":"J Clin Oncol"},{"key":"R16-5-20210209","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1200\/JCO.2006.06.4964","article-title":". Phase i study of depsipeptide in pediatric patients with refractory solid tumors: a Childrens Oncology Group report.","volume":"24","author":"Fouladi","year":"2006","journal-title":"J Clin Oncol"},{"key":"R17-5-20210209","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2006.09.1694","article-title":". Phase i trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Childrens Oncology Group.","volume":"25","author":"Malempati","year":"2007","journal-title":"J Clin Oncol"},{"key":"R18-5-20210209","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.2006.09.5125","article-title":". Phase i trial of g3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: A childrens oncology group study.","volume":"25","author":"Rheingold","year":"2007","journal-title":"J Clin Oncol"},{"key":"R19-5-20210209","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/1078-0432.CCR-06-2270","article-title":". A phase I study of 17-allylaminogeldanamycin in relapsedrefractory pediatric patients with solid tumors: a Childrens Oncology Group study.","volume":"13","author":"Weigel","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R20-5-20210209","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","article-title":". Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Childrens Oncology Group study.","volume":"26","author":"Glade Bender","year":"2008","journal-title":"J Clin Oncol"},{"key":"R21-5-20210209","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/pbc.21274","article-title":". A phase II trial of rebeccamycin analogue (nsc 655649) in children with solid tumors: a Childrens Oncology Group study.","volume":"50","author":"Langevin","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R22-5-20210209","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/pbc.22609","article-title":". A pediatric phase I trial and pharmacokinetic study of ispinesib: a Childrens Oncology Group phase I consortium study.","volume":"55","author":"Souid","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R23-5-20210209","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pbc.22544","article-title":"3rd, Berg S, Blaney S, et al.. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Childrens Oncology Group study.","volume":"55","author":"Beaty","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R24-5-20210209","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/pbc.22407","article-title":". Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (voit) for children with relapsed or refractory solid tumors: a Childrens Oncology Group phase I consortium study.","volume":"54","author":"Wagner","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R25-5-20210209","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.2010.30.7231","article-title":". Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the Childrens Oncology Group phase I consortium.","volume":"29","author":"Aplenc","year":"2011","journal-title":"J Clin Oncol"},{"key":"R26-5-20210209","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2010.30.8387","article-title":". Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsedrefractory solid tumors or myelodysplastic syndrome: a Childrens Oncology Group phase i consortium report.","volume":"29","author":"Berg","year":"2011","journal-title":"J Clin Oncol"},{"key":"R27-5-20210209","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1158\/1078-0432.CCR-12-0078","article-title":". A phase i trial and pharmacokinetic study of aflibercept (vegf trap) in children with refractory solid tumors: A childrens oncology group phase i consortium report.","volume":"18","author":"Glade Bender","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R28-5-20210209","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1158\/1078-0432.CCR-11-3284","article-title":". A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Childrens Oncology Group phase I consortium report.","volume":"18","author":"Widemann","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R29-5-20210209","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pbc.24271","article-title":". A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Childrens Oncology Group phase I consortium study (advl0916).","volume":"60","author":"Muscal","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R30-5-20210209","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":". Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Childrens Oncology Group.","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R31-5-20210209","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1200\/JCO.2007.11.6103","article-title":". Phase II trial of irinotecan in children with refractory solid tumors: a Childrens Oncology Group study.","volume":"25","author":"Bomgaars","year":"2007","journal-title":"J Clin Oncol"},{"key":"R32-5-20210209","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1158\/1078-0432.CCR-11-3251","article-title":". Pediatric phase I trial and pharmacokinetic study of mln8237, an investigational oral selective small-molecule inhibitor of aurora kinase a: a Childrens Oncology Group phase I consortium study.","volume":"18","author":"Mosse","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R33-5-20210209","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.2012.47.0914","article-title":". Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a Childrens Oncology Group phase I consortium report.","volume":"31","author":"Glade Bender","year":"2013","journal-title":"J Clin Oncol"},{"key":"R34-5-20210209","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/pbc.24874","article-title":". Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Childrens Oncology Group study.","volume":"61","author":"Bagatell","year":"2014","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000000474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T15:14:56Z","timestamp":1718205296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201604000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000474","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}